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i.org/1(CAD) is under debate, particularly in community-dwelling frail patients at high risk of
death. In this retrospective observational study on 2,597 community-dwelling patients aged
‡65 years with a previous hospitalization for CAD, we estimated mortality risk assessed
with the Multidimensional Prognostic Index (MPI), based on the Standardized Multidi-
mensional Assessment Schedule for Adults and Aged Persons (SVaMA), used to determine
accessibility to homecare services/nursing home admission in 2005 to 2013 in the Padua
Health District, Veneto, Italy. Participants were categorized as having mild (MPI-SVaMA-
1), moderate (MPI-SVaMA-2), and high (MPI-SVaMA-3) baseline mortality risk, and
propensity scoreeadjusted hazard ratios (HRs) of 3-year mortality rate were calculated
according to statin treatment in these subgroups. Greater MPI-SVaMA scores were
associated with lower rates of statin treatment and higher 3-year mortality rate (MPI-S-
VaMA-1[ 23.4%; MPI-SVaMA-2[ 39.1%; MPI-SVaMA-3[ 76.2%). After adjusting for
propensity score quintiles, statin treatment was associated with lower 3-year mortality risk
irrespective of MPI-SVaMA group (HRs [95% conﬁdence intervals] 0.45 [0.37 to 0.55], 0.44
[0.36 to 0.53], and 0.28 [0.21 to 0.39] in MPI-SVaMA-1, -2, and -3 groups, respectively
[interaction test p [ 0.202]). Subgroup analyses showed that statin treatment was also
beneﬁcial irrespective of age (HRs [95% conﬁdence intervals] 0.38 [0.27 to 0.53], 0.45 [0.38
to 0.54], and 0.44 [0.37 to 0.54] in 65 to 74, 75 to 84, and ‡85 year age groups, respectively
[interaction test p[ 0.597]). In conclusion, in community-dwelling frail older patients with
CAD, statin treatment was signiﬁcantly associated with reduced 3-year mortality rate
irrespective of age and multidimensional impairment, although the frailest patients were
less likely to be treated with statins.  2016 Elsevier Inc. All rights reserved. (Am J
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Coronary Artery Disease/Statins and Mortality in Frail Older CAD Patients 1625Furthermore, recent guidelines have shown that the clinical
decision-making on statin prescription in older patients only
rarely is based on mortality risk stratiﬁcation,4,5 resulting in
many hospitalized or community-dwelling older patients
with CAD not receiving statins. In older age, mortality risk
stratiﬁcation should be based on information on co-morbidity
and functional status,6 and it is best performed using in-
struments based on multidimensional Comprehensive Geri-
atric Assessment (CGA), integrating information of several
domains of health and function.7 Recently, a Multidimen-
sional Prognostic Index (MPI) derived from a standardized
CGA has been developed and validated for mortality risk
assessment in several independent cohorts of hospitalized8
and community-dwelling older subjects9 with acute or
chronic diseases. In a large sample of community-dwelling
frail older patients with diabetes mellitus, statin treatment
was associated with a reduced 3-year mortality rate, sug-
gesting that a severely compromised health and functional
status, or a very old age, did not affect the association be-
tween statin treatment and reduced mortality.10 The objective
of the present study was to test the hypothesis that effec-
tiveness of statin treatment in community-dwelling frail older
patients with CAD may vary across strata of mortality risk in
a 3-year follow-up period.
Methods
This was a retrospective observational study conducted
according to the guidelines for Good Clinical Practice and
the Strengthening the Reporting of Observational Studies in
Epidemiology guidelines.11 All consecutive community-
dwelling older subjects aged 65 years in whom a CGA-
based multidimensional assessment using the Standardized
Multidimensional Assessment Schedule for Adults and
Aged Persons (SVaMA) was performed from January 1,
2005, to December 31, 2013, were screened for inclusion in
the study. Patients were included in the analysis if they had
been discharged from hospital with a main diagnosis of
CAD according to International Classiﬁcation of Diseases,
Ninth Revision, 410 to 414 codes and subgroups or ac-
cording to the main SVaMA diagnosis records K74 to K76
(Ischemic Heart Disease [IHD]) within 3 months from the
SVaMA evaluation. The Institutional Review Board of the
Social and Health-Care Local Unit (ULSS) 16, Padua, Italy,
approved this study. Informed consent was given by par-
ticipants who underwent SVaMA evaluation and/or by their
proxies for clinical records to be used in clinical studies. The
mean follow-up was 2.1  2.2 years. The Registry Ofﬁces
of cities where patients were residents at the time of the ﬁrst
evaluation were used to assess vital status during the follow-
up, recording the dates of death from death certiﬁcates.
SVaMA is the instrument ofﬁcially recommended since
2000 by the National Health Care System in the Veneto
Regional Health System for multidimensional assessment by
health professionals to establish accessibility of community-
dwelling older persons to home care services or nursing home
admission. The following SVaMA domains and variables
were used for MPI calculation: (1) age, (2) gender, (3) main
diagnosis, (4) nursing care needs (VIP) assessed by a vali-
dated numeric 11-item scale; (5) cognitive status (VCOG),
assessed by the Short Portable Mental Status Questionnaire;(6) pressure sores risk (VPIA), assessed by the Exton-Smith
Scale; (7) activities of daily living (VADL); (8) mobility
(VMOB) assessed by the Barthel Index; and (9) social sup-
port (VSOC), assessed by a numeric 16-item scale that ex-
plores the presence of a support network during day and
night. The following cut-off points were estimated for the
normalized MPI-SVaMA 1-year mortality rate prediction:
0 to 0.33 (MPI-SVaMA-1 mild risk), 0.34 to 0.47 (MPI-
SVaMA-2 moderate risk), 0.48-1.0 (MPI-SVaMA-3 severe
risk). To calculate the MPI-SVaMA, software for Windows
may be downloaded for free at the following address: http://
www.mpiage.eu (English version). Further information on
reliability, accuracy, calibration, and validation of the MPI
based on the SVaMA can be found elsewhere.9 To extract the
individual medication use, the whole study population was
linked to the Pharmaceutical Prescription database of the
Azienda ULSS 16, Padua. Statins and other drug pre-
scriptions were determined according to the Anatomical
Therapeutic Chemical codes. Statin prescription was deter-
mined by C10 Anatomical Therapeutic Chemical code.
Subjects were considered statin users if they received statin
prescriptions after the ﬁrst registered evidence of the CAD
diagnosis. In the present study, we included all statin users
who achieved a treatment adherence coverage, that is, the
ratio between treatment duration (in days) and individual
follow-up duration (in days) of at least 90% for the ﬁrst year
and 80% and 70% when considering the outcome at 2 and 3
years of follow-up, respectively. We deﬁned statin nonusers
as the older subjects who never received statin prescriptions.
We included prescriptions within 3 months after initial
diagnosis of CAD. As a proxy of patients’ polypharmacy, we
used the mean monthly past treatment rate deﬁned as the total
number of drug boxes taken before the enrollment divided by
the total number of months between the ﬁrst prescription and
enrollment.
Frequencies (percentages) and mean restandard deviation
(SD) were used to describe categorical and continuous
baseline variables, respectively. Comparisons between men
and women were performed using the Pearson chi-square test
and ManneWhitney U test, whereas linear trends across
MPI-SVaMA risk subgroups were analyzed using analysis of
variance models or the ManteleHaenszel chi-square tests for
continuous or categorical variables, respectively. Mortality
rates were computed as the number of deaths per 100 person-
years and compared using Poisson regression models. To
control possible confounding effects on the association be-
tween statins treatment and mortality risk, the propensity
score (PS) method was applied.12 PS logistic regression
models were built to predict the probability of receiving
statins according to all variables used for the calculation of
MPI-SVaMA at treatment assignment: age, gender, VIP,
VCOG, VPIA, VADL, VMOB, VSOC, the main diagnoses
of fractures, cancer, dementia, stroke, hypokinetic syndrome
and cardiovascular, respiratory, neurologic, or other diseases,
and the past treatment rate of any drug (in tertiles). PS logistic
models were selected stepwise, and model building was
stopped when an adequate balance of covariates was ach-
ieved.12 Residual imbalances of covariates in PS quintiles
were assessed at each step with a 2-way analysis of variance
where each confounder was considered as an outcome and PS
quintiles and treatment as factors. To verify that the data can
Table 1
Baseline characteristics of community-dwelling frail older patients with coronary artery disease (CAD) divided according to their Multidimensional Prognostic
Index (MPI) risk group based on the Standardized Multidimensional Assessment Schedule for Adults and Aged Persons (SVaMA)
Variable All MPI-SVaMA-1
Mild risk
MPI-SVaMA-2
Moderate risk
MPI-SVaMA-3
Severe risk
p-value (test
for trend)
Patients (%) 2597 (100%) 785 (30.2%) 1096 (42.2%) 716 (27.6%) ——
Age at SVaMA evalutation (years) 83.937.35 81.947.34 84.747.21 84.877.15 <0.001
Sex n males (%) 1155 (44.47%) 249 (31.72%) 452 (41.24%) 454 (63.41%) <0.001
Activities of daily living 42.5018.64 21.6414.72 47.8513.00 57.175.26 <0.001
Cognitive status 5.203.60 3.413.13 5.243.43 7.103.32 <0.001
Nursing care needs 7.888.42 2.824.69 6.206.35 15.998.58 <0.001
Mobility 30.5511.85 17.0111.03 34.676.84 39.102.15 <0.001
Pressure sore risk 5.056.26 0.141.28 4.335.27 11.555.30 <0.001
Social support 159.5970.01 142.0870.69 163.5967.77 172.6668.93 <0.001
Number of medications* 41.4259.86 46.0762.18 40.7459.35 37.3657.75 0.003
Main associated diagnoses
Fractures 44 (1.69%) 13 (1.66%) 21 (1.92%) 10 (1.40%) <0.001
Cancer 419 (16.13%) 122 (15.54%) 170 (15.51%) 127 (17.74%)
Dementia 583 (22.45%) 182 (23.18%) 271 (24.73%) 130 (18.16%)
Stroke 173 (6.66%) 34 (4.33%) 67 (6.11%) 72 (10.06%)
Cardiovascular disease 615 (23.68%) 226 (28.79%) 254 (23.18%) 135 (18.85%)
Respiratory disease 81 (3.12%) 20 (2.55%) 31 (2.83%) 30 (4.19%)
Neurologic disease 110 (4.24%) 43 (5.48%) 38 (3.47%) 29 (4.05%)
Hypokinetic syndrome 326 (12.55%) 57 (7.26%) 154 (14.05%) 115 (16.06%)
Other diseases 246 (9.47%) 88 (11.21%) 90 (8.21%) 68 (9.50%)
Follow-up time (years) 2.052.24 2.812.53 2.042.14 1.241.68 <0.001
Mortality at 1 year ev/py (ir %)† 1081/1765 (61.2%) 217/619 (35.1%) 431/771 (55.9%) 433/375 (115.4%) <0.001
Mortality at 2 years ev/py (ir %)† 1336/2941 (45.4%) 283/1079 (26.2%) 543/1282 (42.4%) 510/579 (88.0%) <0.001
Mortality at 3 years ev/py (ir %)† 1519/3789 (40.1%) 338/1442 (23.4%) 641/1638 (39.1%) 540/709 (76.2%) <0.001
* Number of all medications per month, taken before the patient’s enrollment.
† ev/py: events/person-years, ir %: incidence rate (number of events per 100 person-years).
1626 The American Journal of Cardiology (www.ajconline.org)support a comparison of treatment and control groups that are
balanced on all covariates, the distribution of the estimated
PSs for the treated and control groups should be checked for
adequate overlap. This can be accomplished by creating
overlapping histograms or by comparing quintiles of the
estimated PSs for the treatment and control groups. If there is
no overlap in the PS distribution across exposure groups, then
no estimates of the treatment effect can be made. For this
reason, subjects in treated and control groups with
nonoverlapping PS distribution were excluded from the
analysis. Separate PS logistic models were run for the overall
sample and MPI-SVaMA subgroups. Multivariate and PS
quintileseadjusted Cox regression models were used to
assess the effect of statins use on 3-year mortality rate, and
results were reported as hazard ratios (HRs) and 95% conﬁ-
dence intervals (CIs). In addition, to check the robustness of
our ﬁndings, a 5 to 1 greedy 1:1 PS-matching algorithm was
performed. PS 1:1 matching identiﬁed a unique matched
control for each patient treated with statins. Adequacy of
covariate balance in the matched sample was eventually
assessed with the McNemar or Wilcoxon signed rank test.
For the overall sample and for speciﬁc MPI-SVaMA risk
subgroups, adjusted HRs of statins use for 3-year mortality
were reported along with numbers of events and subjects per
group and mortality rates. Multivariate models included
statin treatment, age, gender, main diagnoses, all domains of
MPI-SVaMA, and the past treatment rates of any drug ascovariates. As the PS-matched sample did not consist of in-
dependent observations, a marginal survival model with
robust standard errors was used. p Values assessing the
presence of a heterogeneous effect of statin treatment be-
tween MPI-SVaMA risk subgroups were also calculated and
reported.13 Two-sided p values <0.05 were considered sta-
tistically signiﬁcant. All analyses were performed using the
SAS 9.1.3 statistical package (SAS Institute, Cary, North
Carolina).
Results
Of a total population of 22,744 subjects aged 65 years
who underwent a SVaMA evaluation over the study period,
3,172 (13.95%) were diagnosed with CAD. Of these, 334 and
241 subjects were excluded from analysis because of a time
lag >3 months between CAD diagnosis and SVaMA eval-
uation or statin prescription, respectively. Thus, the ﬁnal
study population included 2,597 patients, 1,155 men (44.5%)
and 1,442 women, with a mean age of 83.9 mo7.4 years. Men
were younger than women (81.7 ea7.3 vs 85.7 856.8 years,
p <0.001) and had higher MPI (0.37 ea0.1 vs 0.31 0.0.1,
p <0.001), VIP (8.96 0.8.7 vs 7.01 .78.1, p <0.001), prev-
alence of cancer (25.8% vs 8.4%, p <0.001), and mortality
rate over the 3-year follow-up (48.1% vs 34.5%, p <0.001).
Women had a greater cognitive impairment than men
(VCOG 5.52  3.5 vs 4.80  3.5, p <0.001) and a higher
Table 2
Pre-matching baseline characteristics of frail community-dwelling older patients with coronary artery disease (CAD) according to statin treatment
Not treated Treated p-value Standardized
mean difference
Patients (%) 1532 (58.99%) 1065 (41.01%) —— ——
Age at SVaMA evaluation (years) 85.817.10 81.226.84 <0.001 -65.796
Sex (n males, %) 618 (40.34%) 537 (50.42%) <0.001 20.358
Activities of daily living 44.5517.92 39.5519.26 <0.001 -26.856
Cognitive status 5.673.56 4.523.54 <0.001 -32.344
Nursing care needs 7.498.05 8.438.91 0.023 11.164
Mobility 31.6011.48 29.0412.23 <0.001 -21.628
Pressure sore risk 5.486.34 4.446.08 <0.001 -16.648
Social support 162.9069.29 154.8270.80 0.002 -11.536
Fractures 31 (2.02) 13 (1.22) 0.119 -6.359
Cancer 192 (12.53) 227 (21.31) <0.001 23.583
Dementia 385 (25.13) 198 (18.59) <0.001 -15.870
Stroke 98 (6.40) 75 (7.04) 0.517 2.578
Cardiovascular disease 364 (23.76) 251 (23.57) 0.910 -0.451
Respiratory disease 46 (3.00) 35 (3.29) 0.682 1.626
Neurologic disease 74 (4.83) 36 (3.38) 0.071 -7.313
Ipokinetic syndrome 216 (14.10) 110 (10.33) 0.004 -11.534
Other diseases 126 (8.22) 120 (11.27) 0.009 10.274
MPI-SVaMA (continuous) 0.400.11 0.380.11 <0.001 -19.057
MPI-SVaMA -1 mild risk 406 (26.50%) 379 (35.59%) <0.001 19.732
MPI- SVaMA-2 moderate risk 669 (43.67%) 427 (40.09%) -7.250
MPI- SVaMA-3 severe risk 457 (29.83%) 259 (24.32%) -12.427
Number of medications* 1tertile-Low 717 (46.80%) 187 (17.56%) <0.001 -65.907
Number of medications* 2tertile-Med 477 (31.14%) 344 (32.30%) 2.503
Number of medications* 3tertile-High 338 (22.06%) 534 (50.14%) 61.130
MPI ¼ Multidimensional Prognostic Index; SVaMA ¼ Standardized Multidimensional Assessment Schedule for Adults and Aged Persons.
* Number of all medications prescribed within one year before patient’s enrollment.
Table 3
Overall and subgroup analyses for frail community-dwelling older patients with coronary artery disease (CAD) statin users vs non-users: multivariate and
propensity score (PS) quintiles adjusted models
Deaths Patients Person-
years
Three-year mortality rate
(n events per 100 person-years)
Multivariable models* PS quintiles adjusted
models
All Statin use Change† HR 95% CI p-value HR 95% CI p-value
No Yes
MPI-SVaMA risk group
MPI-SVaMA-1 mild risk 338 785 1442 23.4 33.1 15.7 -17.4 0.36 0.29-0.43 <0.001 0.45 0.37-0.55 <0.001
MPI-SVaMA-2 moderate risk 641 1096 1638 39.1 53.8 24.6 -29.2 0.39 0.32-0.47 <0.001 0.44 0.36-0.53 <0.001
MPI-SVaMA-3 severe risk 540 716 709 76.2 129.3 38.1 -91.2 0.19 0.14-0.28 <0.001 0.28 0.21-0.39 <0.001
Age
65-74.9 years 182 326 534 34.1 64.5 24.1 -40.4 0.24 0.16-0.34 <0.001 0.38 0.27-0.53 <0.001
75-84.9 years 574 1051 1637 35.1 53.3 23.4 -29.9 0.34 0.28-0.41 <0.001 0.45 0.38-0.54 <0.001
85 years 763 1220 1618 47.2 62.0 24.4 -37.6 0.37 0.30-0.45 <0.001 0.44 0.37-0.54 <0.001
All 1519 2597 3789 40.1 59.0 23.8 -35.2 0.35 0.30-0.39 <0.001 0.44 0.39-0.49 <0.001
MPI-SVaMA ¼ Multidimensional Prognostic Index-Standardized Multidimensional Assessment Schedule for Adults and Aged Persons.
* Models were adjusted for: age at SVaMA evaluation, sex, nursing care needs (VIP), cognitive status (VCOG), pressure sores risk (VPIA), activities of daily
living (VADL), mobility (VMOB), social support (VSOC) (all MPI-SVaMA domains), the needing of care assistants, the main diagnoses of fractures, cancer,
dementia, stroke, hypokinetic syndrome and cardiovascular, respiratory neurological or other diseases and number of all medications prescribed within one year
before patient’s enrollment (tertiles).
† Difference of mortality rates between statins users versus non-user.
Coronary Artery Disease/Statins and Mortality in Frail Older CAD Patients 1627prevalence of dementia (26.4% vs 17.5%, p <0.001). Past
drug treatment of any drug was similar in men and women,
but the proportion of subjects starting statin treatment was
greater in men than in women (46.5% vs 36.6%, p <0.001).Table 1 lists the characteristics of older patients with
CAD divided according to their MPI-SVaMA risk group:
785 (30.2%), 1,096 (42.2%), and 716 (27.6%) were at mild,
moderate, and severe risk of mortality, respectively. Patients
1628 The American Journal of Cardiology (www.ajconline.org)with greater MPI-SVaMA values were more likely to be
men (p for trend <0.001) and older (p for trend <0.001) and
had signiﬁcantly greater VADL, VCOG, VIP, VMOB,
VPIA, and VSOC scores (p for trend <0.001 for all do-
mains). Three-year mortality rates were 23.4%, 39.1%, and
76.2% in the mild, moderate, and severe MPI-SVaMA risk
subgroups, respectively (p for trend <0.001). Overall, 1,065
older patients with CAD (41.01% of the total study popu-
lation) were treated with statins. Statin users were younger
(p ¼ 0.001) and included more men than statin nonusers
(p <0.001; Table 2). Statin users had less impairment in
VCOG (p <0.001), VPIA (p <0.001), VADL (p <0.001),
and VMOB (p <0.001) scores, lower MPI-SVaMA values
(p <0.001), and greater VIP values (p ¼ 0.023) than statin
nonusers. Moreover, statin users were more frequently in the
MPI-SVaMA-1 group (35.6% vs 26.5%, p <0.001) and in
the highest tertile of medication number than nonusers
(3-tertile, 50.1% vs 22.1%, p <0.001).
Multivariate analysis adjusted for age, gender, main di-
agnoses, MPI-SVaMA domains, and the past treatment rate
showed that statin treatment was associated with lower
3-year mortality risk, irrespective of the MPI-SVaMA risk
subgroup (p for trend <0.001; Table 3). A statistically
signiﬁcant association between statin treatment and lower
mortality prevailed after adjustment for PS quintiles.
Similarly, statin treatment was associated with lower mor-
tality risk within each risk group of MPI-SVaMA. HRs
(95% CIs) were 0.45 (0.37 to 0.55), 0.44 (0.36 to 0.53), and
0.28 (0.21 to 0.39) for MPI-SVaMA-1, MPI-SVaMA-2, and
MPI-SVaMA-3, respectively (interaction test p ¼ 0.202).
The association of statin treatment with lower mortality was
also age independent, with PS quintileseadjusted HRs
(95% CIs) of 0.38 (0.27 to 0.53), 0.45 (0.38 to 0.54), and
0.44 (0.37 to 0.54) in patients aged 65 to 74, 75 to 84, and
85 years, respectively (interaction test p ¼ 0.597). The
PS-based greedy matching algorithm successfully matched
733 of 1,065 statin-treated patients. The results fully sup-
ported overall analyses and conclusions. The adequacy of
covariate balance in the matched sample is provided in
Supplementary Table 1. Results of statin treatment effects
from marginal univariate Cox regression models, with
robust standard errors, were fully overlapping with those
reported in Table 3 (Supplementary Table 2).
Discussion
Our real-world retrospective observational study
demonstrated that high adherence to statin treatment was
associated with lower 3-year mortality rate in community-
dwelling frail older patients with CAD and that this asso-
ciation was independent of overall health and functional
status or advanced age. Therefore, the present ﬁndings
suggested that even a substantially compromised health or
functional status, or an extremely advanced age, should not
contraindicate statin use as secondary prevention in older
patients with CAD, provided that patients may have high
adherence to treatment.
Only few studies and meta-analyses of randomized
clinical trials (RCTs) have suggested a reduced mortality in
older patients treated with statins.1,14 Moreover, the ﬁnding
of ageestatin interaction in observational studies, withreduced protection over the age of 80 years,15 has raised
controversies about the prescription of statins in older pa-
tients. The prevalence of statin use in this older population
with CAD (41%) is comparable to recent population-based
studies conducted on older sample without stratiﬁcation
for the presence of cardiovascular disease1,16 but much
lower than that reported in a study of older people with
IHD.17 This low prevalence of statin use might reﬂect the
reluctance of physicians to treat our older patients who were
frail because of a burden of concomitant diseases, functional
limitations, and social problems. In particular, with
advancing age, quality of life is increasingly affected by
frailty, cognitive decline, and the consequences of a variety
of chronic diseases, including cardiovascular disease.3,18 At
present, the impact of statin treatment in older subjects on
outcomes such as frailty, physical and cognitive function,
and institutionalization is controversial.1,16,19,20
In a Canadian population-based cohort of older patients
who survived myocardial infarction, the association between
the use of chronic (statins) and acute therapy (reperfusion)
and life expectancies was seen not only in patients with
limited prognosis but also in those who were expected to live
for 10 to 15 years,21 suggesting that the persistent treatment
care gaps may reﬂect clinicians’ synthesis about frailty
and life-expectancy gains.19 A recent Australian population-
based study suggested that optimal medical therapy was
associated with better survival in men with IHD, whereas
exposure to2 of the 4 guideline-recommended medications
was associated with lowest risk of institutionalization,
independently of the presence of geriatric syndromes (frailty,
falls, urinary incontinence, and cognitive impairment).17
Of the 4 guideline-recommended medications, antiplatelet
medications followed by statins appeared to confer the
greatest beneﬁt to participant survival.17 Furthermore, a
prospective study on 342 patients >65 years surviving after
an acute coronary syndrome suggested that frailty, cognitive
impairment, and co-morbidity were associated with worse
long-term prognosis, particularly all-cause mortality.22 On
the contrary, a retrospective analysis failed to show a survival
beneﬁt attributable to statins in subjects aged 80 years
hospitalized with acute or chronic manifestations of CAD,23
although lack of inclusion of several common co-morbidities
such as chronic lung disease and cancer may have inﬂuenced
the decision to prescribe statins and might be expected to
favor the statin group.
In the present study, we adopted the MPI based on the
SVaMA to evaluate the mortality risk,9,24,25 whose variables
include multidimensional assessment of patients’ clinical,
functional, cognitive, and social status. In previous studies,
the MPI score was extremely accurate in predicting mor-
tality in different settings,25 with a signiﬁcantly higher
predictive power for all-cause mortality compared to 3 other
widely used frailty instruments.26 In the present study,
notwithstanding indications, statin-treated patients were
younger; had less clinical, cognitive, and functional im-
pairments; and had a signiﬁcant lower mortality risk than
statin nonusers. To address this selection bias, PS-matching
methods were used to deﬁne cohorts which differed only for
statin treatment. Both the PS-adjusted models and the ana-
lyses within the PS-matched cohorts conﬁrmed that the
beneﬁt from statin treatment was evident in patients with
Coronary Artery Disease/Statins and Mortality in Frail Older CAD Patients 1629CAD independently of MPI risk group. The subgroup ana-
lyses for heterogeneity, moreover, showed that the reduction
in mortality associated with statin treatment was not
signiﬁcantly different in patients with different mortality
risk. In fact, the largest relative reduction in mortality
associated with statin use was observed in patients with the
greatest MPI-estimated overall risk.
Some limitations of the present study have to be
acknowledged. PS matching can address selection bias;
however, residual confounding due to baseline unobserved
covariates should play still a role and those events which
can happen during the follow-up such as some adverse
events which usually drive nonadherence to the treatment.
Unfortunately, we did not have these time-varying cova-
riates, and therefore, we cannot use more appropriated and
sophisticated statistical methods as marginal structural
models. The efﬁcacy of statins was assessed only in terms of
reduced all-cause mortality, without analyzing the different
causes of deaths or taking into account nonfatal events.
Furthermore, we included only statin-adherent patients, who
obviously had no or only minor adverse events. Therefore,
the patients who were not treated with statins in this cohort
were more likely to have adverse events, which may limit
the upside of a more liberal use of statins in older age. Also,
we did not have laboratory variables (serum cholesterol and
other lipids) available for our analysis, to investigate
whether they might have an impact on treatment decisions.
Finally, because the follow-up was limited to 3 years, we
cannot exclude that signiﬁcant difference in effectiveness in
patients with different mortality risk could emerge with a
longer observation time.
Real-world prospective trials speciﬁcally designed for
inclusion of frail older patients with or without CAD and
examining the impact of statin treatment on important
clinical outcomes in older age are now called for.22 The
STAtins for Reducing Events in the Elderly trial will be the
ﬁrst RCT determining the effects of statin therapy versus
placebo on overall survival or disability-free survival over
an average 5-year treatment period in an apparently healthy
elderly cohort of approximately 12,000 older Australians
(>70 years) living independently in the community.18 Until
the results of this trial are known, treatment decisions
regarding administration of cholesterol-lowering agents for
very old and frail patients must be based on observational
studies and extrapolations from the RCTs in younger peo-
ple. The lower mortality rate associated with high adherence
to statin use in the present retrospective observational study
may suggest a signiﬁcant impact of statin treatment also in
community-dwelling multimorbid and frail older patients
with CAD to home care services or nursing home
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